Cargando…
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular therapeutic target that is expressed by GBM: h...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940806/ https://www.ncbi.nlm.nih.gov/pubmed/20809959 http://dx.doi.org/10.1186/1471-2407-10-468 |
_version_ | 1782186846989582336 |
---|---|
author | Kuan, Chien-Tsun Wakiya, Kenji Herndon, James E Lipp, Eric S Pegram, Charles N Riggins, Gregory J Rasheed, Ahmed Szafranski, Scott E McLendon, Roger E Wikstrand, Carol J Bigner, Darell D |
author_facet | Kuan, Chien-Tsun Wakiya, Kenji Herndon, James E Lipp, Eric S Pegram, Charles N Riggins, Gregory J Rasheed, Ahmed Szafranski, Scott E McLendon, Roger E Wikstrand, Carol J Bigner, Darell D |
author_sort | Kuan, Chien-Tsun |
collection | PubMed |
description | BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3). METHODS: We investigated MRP3 by genetic and immunohistochemical (IHC) analysis of human gliomas to determine the incidence, distribution, and localization of MRP3 antigens in GBM and their potential correlation with survival. To determine MRP3 mRNA transcript and protein expression levels, we performed quantitative RT-PCR, raising MRP3-specific antibodies, and IHC analysis with biopsies of newly diagnosed GBM patients. We used univariate and multivariate analyses to assess the correlation of RNA expression and IHC of MRP3 with patient survival, with and without adjustment for age, extent of resection, and KPS. RESULTS: Real-time PCR results from 67 GBM biopsies indicated that 59/67 (88%) samples highly expressed MRP3 mRNA transcripts, in contrast with minimal expression in normal brain samples. Rabbit polyvalent and murine monoclonal antibodies generated against an extracellular span of MRP3 protein demonstrated reactivity with defined MRP3-expressing cell lines and GBM patient biopsies by Western blotting and FACS analyses, the latter establishing cell surface MRP3 protein expression. IHC evaluation of 46 GBM biopsy samples with anti-MRP3 IgG revealed MRP3 in a primarily membranous and cytoplasmic pattern in 42 (91%) of the 46 samples. Relative RNA expression was a strong predictor of survival for newly diagnosed GBM patients. Hazard of death for GBM patients with high levels of MRP3 RNA expression was 2.71 (95% CI: 1.54-4.80) times that of patients with low/moderate levels (p = 0.002). CONCLUSIONS: Human GBMs overexpress MRP3 at both mRNA and protein levels, and elevated MRP3 mRNA levels in GBM biopsy samples correlated with a higher risk of death. These data suggest that the tumor-associated antigen MRP3 has potential use for prognosis and as a target for malignant glioma immunotherapy. |
format | Text |
id | pubmed-2940806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29408062010-10-06 MRP3: a molecular target for human glioblastoma multiforme immunotherapy. Kuan, Chien-Tsun Wakiya, Kenji Herndon, James E Lipp, Eric S Pegram, Charles N Riggins, Gregory J Rasheed, Ahmed Szafranski, Scott E McLendon, Roger E Wikstrand, Carol J Bigner, Darell D BMC Cancer Research Article BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3). METHODS: We investigated MRP3 by genetic and immunohistochemical (IHC) analysis of human gliomas to determine the incidence, distribution, and localization of MRP3 antigens in GBM and their potential correlation with survival. To determine MRP3 mRNA transcript and protein expression levels, we performed quantitative RT-PCR, raising MRP3-specific antibodies, and IHC analysis with biopsies of newly diagnosed GBM patients. We used univariate and multivariate analyses to assess the correlation of RNA expression and IHC of MRP3 with patient survival, with and without adjustment for age, extent of resection, and KPS. RESULTS: Real-time PCR results from 67 GBM biopsies indicated that 59/67 (88%) samples highly expressed MRP3 mRNA transcripts, in contrast with minimal expression in normal brain samples. Rabbit polyvalent and murine monoclonal antibodies generated against an extracellular span of MRP3 protein demonstrated reactivity with defined MRP3-expressing cell lines and GBM patient biopsies by Western blotting and FACS analyses, the latter establishing cell surface MRP3 protein expression. IHC evaluation of 46 GBM biopsy samples with anti-MRP3 IgG revealed MRP3 in a primarily membranous and cytoplasmic pattern in 42 (91%) of the 46 samples. Relative RNA expression was a strong predictor of survival for newly diagnosed GBM patients. Hazard of death for GBM patients with high levels of MRP3 RNA expression was 2.71 (95% CI: 1.54-4.80) times that of patients with low/moderate levels (p = 0.002). CONCLUSIONS: Human GBMs overexpress MRP3 at both mRNA and protein levels, and elevated MRP3 mRNA levels in GBM biopsy samples correlated with a higher risk of death. These data suggest that the tumor-associated antigen MRP3 has potential use for prognosis and as a target for malignant glioma immunotherapy. BioMed Central 2010-09-01 /pmc/articles/PMC2940806/ /pubmed/20809959 http://dx.doi.org/10.1186/1471-2407-10-468 Text en Copyright ©2010 Kuan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kuan, Chien-Tsun Wakiya, Kenji Herndon, James E Lipp, Eric S Pegram, Charles N Riggins, Gregory J Rasheed, Ahmed Szafranski, Scott E McLendon, Roger E Wikstrand, Carol J Bigner, Darell D MRP3: a molecular target for human glioblastoma multiforme immunotherapy. |
title | MRP3: a molecular target for human glioblastoma multiforme immunotherapy. |
title_full | MRP3: a molecular target for human glioblastoma multiforme immunotherapy. |
title_fullStr | MRP3: a molecular target for human glioblastoma multiforme immunotherapy. |
title_full_unstemmed | MRP3: a molecular target for human glioblastoma multiforme immunotherapy. |
title_short | MRP3: a molecular target for human glioblastoma multiforme immunotherapy. |
title_sort | mrp3: a molecular target for human glioblastoma multiforme immunotherapy. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940806/ https://www.ncbi.nlm.nih.gov/pubmed/20809959 http://dx.doi.org/10.1186/1471-2407-10-468 |
work_keys_str_mv | AT kuanchientsun mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT wakiyakenji mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT herndonjamese mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT lipperics mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT pegramcharlesn mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT rigginsgregoryj mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT rasheedahmed mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT szafranskiscotte mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT mclendonrogere mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT wikstrandcarolj mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy AT bignerdarelld mrp3amoleculartargetforhumanglioblastomamultiformeimmunotherapy |